1. Sweden Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Probi AB (publ)

Probi AB (publ)

PROB.ST
Probi AB (publ)SE flagStockholm Stock Exchange
348.00
SEK
- -
- -
3.97BMarket Cap
Probi AB (publ)
PROB.ST
(Stockholm Stock Exchange)

Recent

price

348.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
TTM
FRC
6.85
6.6
8.1
9.73
10.39
10.72
14.03
22.36
46.71
53.73
53.02
54.96
62.94
57.76
54.26
55.09
55.33
Revenue per Share
0.81
1.08
1.38
1.45
1.4
1.56
2.25
5.08
10.73
6.06
6.69
7.54
8.14
7.3
3.57
1.48
0.96
Basic EPS, GAAP
0.97
1.04
2.28
0.74
1.83
1.12
2.44
4.41
7.53
10.48
9.99
12.15
8.78
9.8
8.03
2.75
6.69
Free Cash Flow per Basic Share
- -
- -
0.47
0.94
0.71
0.71
0.71
0.8
0.96
1
- -
- -
1
1.1
1.3
1.3
1.3
Dividend per Share
0.6
1.68
3.06
4.57
5.3
6.86
8.41
12.68
28.45
28.78
35.47
43.16
50.29
56.49
58.75
58.93
- -
Book Value per Share
8.14
9.12
10.43
10.01
10.78
10.64
12
14.87
2.52
10.27
20.18
31.08
38.73
50.48
59.17
60.4
62.07
Tangible Book Value per Share
10
10
10
10
10
10
10
10
9
11
11
11
11
11
11
11
11
Basic Weighted Avg Shares
68
65
80
95
100
104
136
216
443
612
604
626
717
658
618
628
630
Sales/Revenue/Turnover
15.07
21.09
22.51
21.55
17.14
17.52
21.11
27.02
27.05
17
16.74
17.81
17.25
16.6
8.18
1.8
0.49
Operating Margin (%)
5
5
9
9
6
5
9
6
33
53
54
72
73
73
86
96
101
Depreciation Expense
8
11
14
14
14
15
22
49
102
69
76
86
93
83
41
17
11
Net Income, GAAP
35.66
26.67
26.98
27.23
26.29
22.81
22.52
22.27
19.6
25.16
22.64
21.58
22.81
22.61
21.84
3.24
12.29
Effective Tax Rate (%)
11.76
16.42
17
14.94
13.45
14.53
16.05
22.71
22.97
11.29
12.62
13.72
12.92
12.63
6.57
2.68
1.73
Profit Margin (%)
65
78
95
94
102
101
111
139
-20
84
206
292
324
388
454
462
472
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
47
31
63
54
38
61
LT Debt
103
114
123
116
123
131
146
187
892
885
1,028
1,152
1,115
1,266
1,411
1,369
1,368
Total Equity
6.64
9.32
11.15
12.43
10.59
10.98
15.79
27.03
14.78
7.15
7.09
7.38
8.01
6.75
2.8
0.75
- -
Return on Invested Capital (%)
406.41
97.57
58.8
37.88
28.19
25.6
29.51
48.16
33.56
14.69
15.68
16.4
16.09
12.63
5.82
2.56
5.42
Return on Capital (%)
- -
94.79
58.01
37.87
28.19
25.6
29.51
48.14
51.87
23.11
20.83
19.17
17.41
13.67
6.19
2.51
3.23
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
ST Debt
15
21
20
LT Borrowings
- -
- -
- -
LT Finance Leases
37
68
61
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
2,389
3,304
3,019

Working Capital

FRC

•

in mil. unless spec.
Mar'24
Jun'24
Sep'24
Total Current Assets
553
563
562
Cash, Cash Equivalents & STI
340
305
349
Accounts Receivable, Net
71
115
63
Inventories
127
126
129
Total Current Liabilities
69
93
90
Payables & Accruals
- -
- -
- -
ST Debt
15
21
20
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
46.24%
6.17%
-2.94%
Free Cash Flow
24.98%
-15.65%
-65.72%
Net Income, GAAP
15.64%
-19.9%
-58.6%
Sales/Revenue/Turnover
23.77%
1.08%
1.52%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
155
175
145
144
618
2023
172
144
156
156
628
2024
152
179
144
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
1.23
1.75
1.09
- -
3.57
2023
1.69
-0.55
0.56
- -
1.48
2024
0.16
0.71
0.31
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
1.3
- -
- -
1.3
2023
- -
1.3
- -
- -
1.3
2024
- -
1.3
- -
- -
- -
Similar Companies
Lotus Ventures Inc. (LTTSF)
Hisamitsu Pharmaceutical Co., Inc. (HTSUF)
Ovation Science Inc. (OVATF)
TILT Holdings Inc. (TLLTF)
Global Health Clinics Ltd. (MJRX.CN)
Provexis plc (PXS.L)
Business
Probi AB (publ) operates as a biotechnology company, focusing on the research, development, production, and global commercialization of scientifically backed probiotic solutions. The company primarily offers its innovative ingredients and finished products to health, pharmaceutical, and food enterprises worldwide. Its comprehensive scientific efforts span various critical health areas, including gastrointestinal well-being, immune system support, bone density, iron absorption, and more recently, metabolic health, as well as solutions tailored for stress, recovery, women's, children's, and senior health. Probi's advanced probiotic strains are incorporated into a diverse array of product formats, such as capsules, tablets, and powders, and integrated into functional food and beverage applications like fruit drinks, shots, and carbonated beverages. The company's clinically documented portfolio, which includes key strains such as Lactiplantibacillus plantarum 299v (LP299V®), is distributed across more than 40 international markets. A notable development in November 2024 saw Symrise AG, the principal shareholder, announce a public takeover bid to acquire remaining shares, aiming to surpass 90% ownership and proceed with delisting Probi from Nasdaq Stockholm. Recent strategic expansions include new product lines for Sports & Active Nutrition by Probi® and Pets by Probi®, addressing performance enhancement and companion animal well-being. The company has also unveiled a new probiotic concept aimed at supporting metabolic health. Probi maintains robust scientific collaborations with numerous academic institutions globally and has fortified its partnership with BLIS Technologies to secure exclusive distribution rights for oral health probiotic strains for both human and pet applications. Additionally, a collaboration with Clasado Biosciences focuses on developing synergistic synbiotic solutions. Founded in 1991, Probi AB (publ) is headquartered in Lund, Sweden.